Abstract
Clinical proteomics studies are extensively being conducted in recent years. We have outlined some views about proteomics progresses for clinical research, via the understanding the molecular mechanisms of carcinogenesis, tumor response to therapy and biomarker identification versus novel therapeutic target-discovery; as well as proteomerelated methods used in cancer research. Integrative concepts of development of novel therapeutic targets and the application of proteomics in drug development are also discussed.
Several aspects are touched including the development of novel therapeutic targets, proteomics as a tool to discover biomarkers, discovery and validation of prognostic and predictive biomarkers, and biobanking versus proteomics.
Finally, we envision the application of clinical proteomics for future personalized cancer therapies can set up a consensus that will be reached amongst the scientific community.
Keywords: Cancer, clinical proteomics, personalized medicine, omics.
Current Proteomics
Title:Clinical Proteomics in Cancer Research
Volume: 10 Issue: 2
Author(s): Elena Lopez, Luis Madero, Gustavo J. Melen, Manuel Ramirez, Dimitrios H. Roukos and William C. Cho
Affiliation:
Keywords: Cancer, clinical proteomics, personalized medicine, omics.
Abstract: Clinical proteomics studies are extensively being conducted in recent years. We have outlined some views about proteomics progresses for clinical research, via the understanding the molecular mechanisms of carcinogenesis, tumor response to therapy and biomarker identification versus novel therapeutic target-discovery; as well as proteomerelated methods used in cancer research. Integrative concepts of development of novel therapeutic targets and the application of proteomics in drug development are also discussed.
Several aspects are touched including the development of novel therapeutic targets, proteomics as a tool to discover biomarkers, discovery and validation of prognostic and predictive biomarkers, and biobanking versus proteomics.
Finally, we envision the application of clinical proteomics for future personalized cancer therapies can set up a consensus that will be reached amongst the scientific community.
Export Options
About this article
Cite this article as:
Lopez Elena, Madero Luis, Melen J. Gustavo, Ramirez Manuel, Roukos H. Dimitrios and Cho C. William, Clinical Proteomics in Cancer Research, Current Proteomics 2013; 10 (2) . https://dx.doi.org/10.2174/15701646112099990001
DOI https://dx.doi.org/10.2174/15701646112099990001 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
Call for Papers in Thematic Issues
Mass spectrometry data acquisition and analysis for proteomics
The Thematic Issue on "Mass spectrometry data acquisition and analysis for proteomics" aims to explore the latest advancements and challenges in the field of proteomics through the lens of mass spectrometry. Proteomics, the large-scale study of proteins and their functions, plays a crucial role in understanding various biological processes and ...read more
Peptides: State-of-Art and Commercialisation Hurdles
The Editors of the Current Proteomics (CP) journal are highly privileged to welcome scientists to submit their scientific research and review articles to be considered for publication in the upcoming thematic issue. The topics should cover various aspects of peptides in regard to their synthetic methodologies, formulation approaches, pharmacological challenges, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Study on Adsorption and Sustained Release of Eucommia ulmoides Oliv. Leaf Extracts on Activated Carbon
Current Drug Delivery The Role of Chromogranin A (CgA) in Monitoring Patients with Prostate Cancer Under Androgen Deprivation Therapy: Comparison with Prostatic Specific Antigen (PSA)
Current Radiopharmaceuticals Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets A Hybrid Discrete Imperialist Competition Algorithm for Gene Selection for Microarray Data
Current Proteomics The First Total Synthesis of Tarennane, a Potent Antioxidant Chalcone Constituent from Tarenna Attenuate or Magnolia Officinalis
Letters in Organic Chemistry DNA Instability at Chromosomal Fragile Sites in Cancer
Current Genomics Chemoprotective and Carcinogenic Effects of tert-Butylhydroquinone and Its Metabolites
Current Drug Metabolism Purinergic Receptors and Pain
Current Pharmaceutical Design TRAIL Gene Therapy: From Preclinical Development to Clinical Application
Current Gene Therapy Inhibition of PCAF by Anacardic Acid Derivative Leads to Apoptosis and Breaks Resistance to DNA Damage in BCR-ABL-expressing Cells
Anti-Cancer Agents in Medicinal Chemistry Tumor-Targeting Peptides and Small Molecules as Anti-Cancer Agents to Overcome Drug Resistance
Current Medicinal Chemistry Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets Synthesis and Biological Evaluation of Scutellaria Flavone Cyclaneaminol Mannich Base Derivatives as Novel CDK1 Inhibitors
Anti-Cancer Agents in Medicinal Chemistry